New biotech firm wants to challenge vaccine giant: "Our product is better and cheaper"

Danish-Swedish biotech company 2A Pharma has taken the company's HPV vaccine into clinical development in record time. If everything goes well, the vaccine will enter a billion-dollar market in five years. "We have the potential to become quite big," says CEO.

Preben Bruun-Nyzell (left) and John Nieland, founders of 2A Pharma.

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles